Dianorm OD Tablets (Gliclazide + Metformin)

• Composition :
  Each tablet contains Gliclazide 30 mg /60 mgmodified release.
• Indications :
  In treatment of NIDDM (type-II) in association with dietary measures in adult only.
• Pharmacodynamics :
  Gliclazide stimulates the release of insulin from pancreatic β-cells, probably by facilitating Ca2+ transport across the β-cell membranes. It decreases the amount of glucose absorbed from the food and the amount of glucose made by liver.
• Dosage and administration :
  One tablet once a day.
• Contraindications :
  Hypersensitivity to the active substance(s) or to any of the excipients.
• Precautions and warnings :
  Hypoglycaemia may occur following administration of sulphonylureas. Metformin may lower vitamin B12 levels. Metformin-associated lactic acidosis has resulted in hypothermia, hypotension, and resistant bradyarrhythmias.
• Use in pregnancy, lactation & pediatrics :
  children. Gliclazide and Metformin combination is not recommended for use in pregnancy, lactation. Safety and effectiveness of Gliclazide and Metformin combination in paediatric patients have not been established.
• Drug interactions :
  Hypoglycaemia may be potentiated when a gliclazide is used concurrently with agents such as: long-acting sulfonamides, tuberculostatics, clarithromycin, salicylates, non-steroidal anti-inflammatory agents, probenecid, beta-blockers. Certain drugs such as diuretics (thiazides, furosemide), corticosteroids oral contraceptives (estrogen plus progestogen) and nicotinic acid may induce hyperglycemia and may lead to loss of control of blood sugar. Gliclazide may potentiate the anticoagulant effect of warfarin and other anticoagulants, dosage adjustments may be necessary.
• Adverse reactions :
  The most commonly reported adverse events nausea, vomiting, diarrhoea, abdominal pain and loss of appetite and hypoglycaemia
• Therapy Area :
  Anti-Diabetic agents